Work

ABCL-568: Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up

Year: 2026

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)02572-3

Authors: Nilanjan Ghosh, Julio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S Lossos, Nirav N Shah, Sarit Assouline, Adam J Olszewski, Seema Naik, Song Pham, Michael C Wei, Connie L Batlevi, Iris To, Wahib S Ead, Sneha Makadia, Elicia Penuel, L Elizabeth Budde

Institutions: Levine Cancer Institute, Wake Forest University, Moffitt Cancer Center, Hospital General Universitario Gregorio Marañón, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Miami Health System, Sylvester Comprehensive Cancer Center, Medical College of Wisconsin, Jewish General Hospital, Brown University, Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, Roche (Canada), Genentech, City Of Hope National Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204691147

FWCI:

Cites:

Cited by:

Related to: 10